You are here
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
PAR-21-162: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)Release Date: 03-29-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024
A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
Release Date: 04-28-2021Open Date: 06-01-2021 Due Dates: Multiple Close Date: 02-21-2024
A. Purpose The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical saf ...SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
PAR-21-082: NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)Release Date: 01-14-2021Open Date: 04-14-2021 Due Dates: Multiple Close Date: 01-15-2024
Purpose This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. A clinical trial is defined by NIH as: "A research study in which one or more human subjects are prospectivel ...SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
PAR-21-114: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)Release Date: 01-25-2021Open Date: 03-05-2021 Due Dates: Multiple Close Date: 01-06-2024
Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treat ...SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health